Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency DiseasesHirokazu Kanegane, Toshio Miyawaki, Shigeaki Nonoyama et al.|Journal of Clinical Immunology|2014Cited by 38
Safety, Tolerability, and Efficacy Of Hizentra® In Japanese Patients With Primary Immunodeficiency Over 48 WeeksKohsuke Imai, Toshio Miyawaki, Hirokazu Kanegane et al.|Journal of Allergy and Clinical Immunology|2014Cited by 1
Efficacy and safety of Hizentra®, a subcutaneous immune globulin, in Japanese patients with primary immunodeficiency diseasesToshio Miyawaki, Toshiro Hara, Hirokazu Kanegane et al.|F1000Research|2012Cited by 0
Erratum to: Efficacy and Safety of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients with Primary Immunodeficiency DiseasesHirokazu Kanegane, Toshio Miyawaki, Kohsuke Imai et al.|Journal of Clinical Immunology|2014Cited by 0
Health-Related Quality Of Life Of Japanese Patients With Primary Immunodeficiency Diseases Receiving IgPro20, a 20% Liquid Subcutaneous Immunoglobulin (Hizentra®)Hirokazu Kanegane, Toshio Miyawaki, Kohsuke Imai et al.|Journal of Allergy and Clinical Immunology|2014Cited by 0